Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

GYMINDA

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 285

NCT06965413

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebo + Tirzepatiden/rn/rn/rn/r
RO7204239 low dose + Tirzepatiden/rn/rn/rn/r
RO7204239 medium dose + Tirzepatiden/rn/rn/rn/r
RO7204239 high dose + Tirzepatiden/rn/rn/rn/r

Not shown

  • Placebo + Tirzepatide: endpoint not reported
  • RO7204239 low dose + Tirzepatide: endpoint not reported
  • RO7204239 medium dose + Tirzepatide: endpoint not reported
  • RO7204239 high dose + Tirzepatide: endpoint not reported